{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:22:58Z","timestamp":1790799778194,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["DP5OD024576"],"award-info":[{"award-number":["DP5OD024576"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA014520"],"award-info":[{"award-number":["P30 CA014520"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006058","name":"St. Baldrick's Foundation","doi-asserted-by":"publisher","award":["SU2C-AACR-DT1113"],"award-info":[{"award-number":["SU2C-AACR-DT1113"]}],"id":[{"id":"10.13039\/100006058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA174750"],"award-info":[{"award-number":["K08 CA174750"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL07899"],"award-info":[{"award-number":["T32 HL07899"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Finding improved therapeutic strategies against T-cell Non-Hodgkin\u2019s Lymphoma (NHL) remains an unmet clinical need. We implemented a theranostic approach employing a tumor-targeting alkylphosphocholine (NM600) radiolabeled with <jats:sup>86<\/jats:sup>Y for positron emission tomography (PET) imaging and <jats:sup>90<\/jats:sup>Y for targeted radionuclide therapy (TRT) of T-cell NHL. PET imaging and biodistribution performed in mouse models of T-cell NHL showed in vivo selective tumor uptake and retention of <jats:sup>86<\/jats:sup>Y-NM600. An initial toxicity assessment examining complete blood counts, blood chemistry, and histopathology of major organs established <jats:sup>90<\/jats:sup>Y-NM600 safety. Mice bearing T-cell NHL tumors treated with <jats:sup>90<\/jats:sup>Y-NM600 experienced tumor growth inhibition, extended survival, and a high degree of cure with immune memory toward tumor reestablishment. <jats:sup>90<\/jats:sup>Y-NM600 treatment was also effective against disseminated tumors, improving survival and cure rates. Finally, we observed a key role for the adaptive immune system in potentiating a durable anti-tumor response to TRT, especially in the presence of microscopic disease.<\/jats:p>","DOI":"10.1038\/s42003-019-0327-4","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:49:58Z","timestamp":1551181798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["90Y-NM600 targeted radionuclide therapy induces immunologic memory in syngeneic models of T-cell Non-Hodgkin\u2019s Lymphoma"],"prefix":"10.1038","volume":"2","author":[{"given":"Reinier","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsti L.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Grudzinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aluicio-Sarduy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Zahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anatoly N.","family":"Pinchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"Massey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana N.","family":"Bitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Sondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary S.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-6731","authenticated-orcid":false,"given":"Christian M.","family":"Capitini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamey P.","family":"Weichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"key":"327_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose, J., Armitage, J., Weisenburger, D. & International, T. C. L. P. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J. Clin. Oncol. 26, 4124\u20134130 (2008).","journal-title":"J. Clin. Oncol."},{"key":"327_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ctrv.2014.08.001","volume":"40","author":"B Coiffier","year":"2014","unstructured":"Coiffier, B. et al. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. Cancer Treat. Rev. 40, 1080\u20131088 (2014).","journal-title":"Cancer Treat. Rev."},{"key":"327_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/asheducation-2011.1.515","volume":"2011","author":"KJ Savage","year":"2011","unstructured":"Savage, K. J. Therapies for peripheral T-cell lymphomas. Hematol. Am. Soc. Hematol. Educ. Program. 2011, 515\u2013524 (2011).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"327_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/2040620713481980","volume":"4","author":"A Shustov","year":"2013","unstructured":"Shustov, A. Novel therapies for peripheral T-cell lymphomas. Ther. Adv. Hematol. 4, 173\u2013187 (2013).","journal-title":"Ther. Adv. Hematol."},{"key":"327_CR5","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.det.2015.05.006","volume":"33","author":"DJ Tandberg","year":"2015","unstructured":"Tandberg, D. J., Craciunescu, O. & Kelsey, C. R. Radiation Therapy for Cutaneous T-Cell Lymphomas. Dermatol. Clin. 33, 703\u2013713 (2015).","journal-title":"Dermatol. Clin."},{"key":"327_CR6","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1365-2133.2011.10728.x","volume":"166","author":"DV Chan","year":"2012","unstructured":"Chan, D. V. et al. Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas. Br. J. Dermatol. 166, 1134\u20131137 (2012).","journal-title":"Br. J. Dermatol."},{"key":"327_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s11864-004-0020-8","volume":"5","author":"AM Evens","year":"2004","unstructured":"Evens, A. M. & Gartenhaus, R. B. Treatment of T-cell non-Hodgkin\u2019s lymphoma. Curr. Treat. Options Oncol. 5, 289\u2013303 (2004).","journal-title":"Curr. Treat. Options Oncol."},{"key":"327_CR8","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2001.19.19.3918","volume":"19","author":"MS Kaminski","year":"2001","unstructured":"Kaminski, M. S. et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin\u2019s lymphomas. J. Clin. Oncol. 19, 3918\u20133928 (2001).","journal-title":"J. Clin. Oncol."},{"key":"327_CR9","doi-asserted-by":"publisher","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher, R. I. et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas. J. Clin. Oncol. 23, 7565\u20137573 (2005).","journal-title":"J. Clin. Oncol."},{"key":"327_CR10","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1200\/JCO.2005.07.040","volume":"23","author":"SJ Horning","year":"2005","unstructured":"Horning, S. J. et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J. Clin. Oncol. 23, 712\u2013719 (2005).","journal-title":"J. Clin. Oncol."},{"key":"327_CR11","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig, T. E. et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma. J. Clin. Oncol. 20, 3262\u20133269 (2002).","journal-title":"J. Clin. Oncol."},{"key":"327_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig, T. E. et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin\u2019s lymphoma. J. Clin. Oncol. 21, 1263\u20131270 (2003).","journal-title":"J. Clin. Oncol."},{"key":"327_CR13","first-page":"251","volume":"29","author":"F Snyder","year":"1969","unstructured":"Snyder, F. & Wood, R. Alkyl and alk-1-enyl ethers of glycerol in lipids from normal and neoplastic human tissues. Cancer Res. 29, 251\u2013257 (1969).","journal-title":"Cancer Res."},{"key":"327_CR14","first-page":"309","volume":"30","author":"JF Soodsma","year":"1970","unstructured":"Soodsma, J. F., Piantadosi, C. & Snyder, F. The biocleavage of alkyl glyceryl ethers in Morris hepatomas and other transplantable neoplasms. Cancer Res. 30, 309\u2013311 (1970).","journal-title":"Cancer Res."},{"key":"327_CR15","doi-asserted-by":"publisher","first-page":"240ra275","DOI":"10.1126\/scitranslmed.3007646","volume":"6","author":"JP Weichert","year":"2014","unstructured":"Weichert, J. P. et al. Alkylphosphocholine analogs for broad-spectrum cancer imaging and therapy. Sci. Transl. Med 6, 240ra275 (2014).","journal-title":"Sci. Transl. Med"},{"key":"327_CR16","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/09553006114550461","volume":"3","author":"EN Ramsden","year":"1961","unstructured":"Ramsden, E. N. A review of experimental work on radioytrium comprising. I. The tissue distribution. 2. The mechanism of deposition in bone. 3. State blood. Int J. Radiat. Biol. Relat. Stud. Phys. Chem. Med 3, 399\u2013410 (1961).","journal-title":"State blood. Int J. Radiat. Biol. Relat. Stud. Phys. Chem. Med"},{"key":"327_CR17","first-page":"302","volume":"2","author":"LA Walker","year":"1964","unstructured":"Walker, L. A. Radioactive Yttrium 90: A Review of Its Properties, Biological Behavior, and Clinical Uses. Acta Radiol. Ther. Phys. Biol. 2, 302\u2013314 (1964).","journal-title":"Acta Radiol. Ther. Phys. Biol."},{"key":"327_CR18","doi-asserted-by":"publisher","first-page":"7419","DOI":"10.1088\/0031-9155\/59\/23\/7419","volume":"59","author":"L J\u00f8dal","year":"2014","unstructured":"J\u00f8dal, L., Le Loirec, C. & Champion, C. Positron range in PET imaging: Non-conventional isotopes. Phys. Med. Biol. 59, 7419\u20137434 (2014).","journal-title":"Phys. Med. Biol."},{"key":"327_CR19","doi-asserted-by":"crossref","unstructured":"Lubberink, M. & Herzog, H. Quantitative imaging of 124I and 86Y with PET. Eur. J. Nucl. Med. Mol. Imaging 38, 10 (2011).","DOI":"10.1007\/s00259-011-1768-2"},{"key":"327_CR20","doi-asserted-by":"publisher","first-page":"8620","DOI":"10.1158\/1078-0432.CCR-04-1134","volume":"10","author":"JF DiJoseph","year":"2004","unstructured":"DiJoseph, J. F. et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma. Clin. Cancer Res. 10, 8620\u20138629 (2004).","journal-title":"Clin. Cancer Res."},{"key":"327_CR21","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","volume":"11","author":"S Demaria","year":"2005","unstructured":"Demaria, S. et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res. 11, 728\u2013734 (2005).","journal-title":"Clin. Cancer Res."},{"key":"327_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687\u2013695 (2014).","journal-title":"J. Clin. Invest."},{"key":"327_CR23","first-page":"27","volume":"5","author":"AS Kimball","year":"2013","unstructured":"Kimball, A. S. & Webb, T. J. The roles of radiotherapy and immunotherapy for the treatment of lymphoma. Mol. Cell Pharmacol. 5, 27\u201338 (2013).","journal-title":"Mol. Cell Pharmacol."},{"key":"327_CR24","doi-asserted-by":"publisher","first-page":"iv57","DOI":"10.1093\/annonc\/mdr176","volume":"22","author":"TX Illidge","year":"2011","unstructured":"Illidge, T. X. When should radiotherapy be used in lymphoma? Ann. Oncol. 22, iv57\u2013iv60 (2011).","journal-title":"Ann. Oncol."},{"key":"327_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1126\/science.1174621","volume":"327","author":"D Lingwood","year":"2010","unstructured":"Lingwood, D. & Simons, K. Lipid rafts as a membrane-organizing principle. Science 327, 46\u201350 (2010).","journal-title":"Science"},{"key":"327_CR26","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2353\/ajpath.2006.050959","volume":"168","author":"YC Li","year":"2006","unstructured":"Li, Y. C., Park, M. J., Ye, S. K., Kim, C. W. & Kim, Y. N. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. Am. J. Pathol. 168, 1107\u20131118 (2006). quiz 1404-1105.","journal-title":"Am. J. Pathol."},{"key":"327_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/07357907.2015.1081691","volume":"33","author":"SJ Lubner","year":"2015","unstructured":"Lubner, S. J. et al. A Phase 1, multi-center, open-label, dose-escalation study of 131I-CLR1404 in subjects with relapsed or refractory advanced solid malignancies. Cancer Invest. 33, 483\u2013489 (2015).","journal-title":"Cancer Invest."},{"key":"327_CR28","doi-asserted-by":"publisher","first-page":"e92572","DOI":"10.1371\/journal.pone.0092572","volume":"9","author":"Y Yoshimoto","year":"2014","unstructured":"Yoshimoto, Y. et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE 9, e92572 (2014).","journal-title":"PLoS ONE"},{"key":"327_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.critrevonc.2018.01.001","volume":"123","author":"L Marcu","year":"2018","unstructured":"Marcu, L., Bezak, E. & Allen, B. J. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. Crit. Rev. Oncol. Hematol. 123, 7\u201320 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"327_CR30","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade, A. A. et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J. Immunol. 180, 3132\u20133139 (2008).","journal-title":"J. Immunol."},{"key":"327_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97\u2013111 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"327_CR32","doi-asserted-by":"publisher","first-page":"6338","DOI":"10.4049\/jimmunol.170.12.6338","volume":"170","author":"M Chakraborty","year":"2003","unstructured":"Chakraborty, M. et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol. 170, 6338\u20136347 (2003).","journal-title":"J. Immunol."},{"key":"327_CR33","doi-asserted-by":"publisher","first-page":"20170157","DOI":"10.1259\/bjr.20170157","volume":"90","author":"EJ Van Limbergen","year":"2017","unstructured":"Van Limbergen, E. J. et al. Combining radiotherapy with immunotherapy: the past, the present and the future. Br. J. Radiol. 90, 20170157 (2017).","journal-title":"Br. J. Radiol."},{"key":"327_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","volume":"114","author":"Y Lee","year":"2009","unstructured":"Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8\u2009+\u2009T cells: changing strategies for cancer treatment. Blood 114, 589\u2013595 (2009).","journal-title":"Blood"},{"key":"327_CR35","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1158\/0008-5472.CAN-09-2982","volume":"70","author":"T Takeshima","year":"2010","unstructured":"Takeshima, T. et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res. 70, 2697\u20132706 (2010).","journal-title":"Cancer Res."},{"key":"327_CR36","doi-asserted-by":"publisher","first-page":"e87415","DOI":"10.1172\/jci.insight.87415","volume":"1","author":"GS Herter-Sprie","year":"2016","unstructured":"Herter-Sprie, G. S. et al. Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. JCI Insight 1, e87415 (2016).","journal-title":"JCI Insight"},{"key":"327_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","volume":"4","author":"J Kang","year":"2016","unstructured":"Kang, J., Demaria, S. & Formenti, S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J. Immunother. Cancer 4, 51 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"327_CR38","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/MOU.0000000000000335","volume":"26","author":"S Mehta","year":"2016","unstructured":"Mehta, S., Illidge, T. & Choudhury, A. Immunotherapy with radiotherapy in urological malignancies. Curr. Opin. Urol. 26, 514\u2013522 (2016).","journal-title":"Curr. Opin. Urol."},{"key":"327_CR39","doi-asserted-by":"publisher","first-page":"S1447","DOI":"10.21037\/jtd.2018.05.107","volume":"10","author":"N Bhalla","year":"2018","unstructured":"Bhalla, N., Brooker, R. & Brada, M. Combining immunotherapy and radiotherapy in lung cancer. J. Thorac. Dis. 10, S1447\u2013S1460 (2018).","journal-title":"J. Thorac. Dis."},{"key":"327_CR40","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1158\/2326-6066.CIR-17-0353","volume":"6","author":"ZS Morris","year":"2018","unstructured":"Morris, Z. S. et al. Tumor-Specific inhibition of in situ vaccination by distant untreated tumor sites. Cancer Immunol. Res 6, 825\u2013834 (2018).","journal-title":"Cancer Immunol. Res"},{"key":"327_CR41","doi-asserted-by":"crossref","unstructured":"Aluicio-Sarduy, E. et al. Simplified and automatable radiochemical separation strategy for the production of radiopharmaceutical quality (86)Y using single column extraction chromatography. Appl. Radiat. Isot. 142, 28\u201331 (2018).","DOI":"10.1016\/j.apradiso.2018.09.016"},{"key":"327_CR42","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/1097-0142(19940201)73:3+<958::AID-CNCR2820731331>3.0.CO;2-E","volume":"73","author":"BG Beatty","year":"1994","unstructured":"Beatty, B. G. et al. Application of the cross-organ beta dose method for tissue dosimetry in tumor-bearing mice treated with a 90Y-labeled immunoconjugate. Cancer 73, 958\u2013965 (1994).","journal-title":"Cancer"},{"key":"327_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/cbr.2005.20.436","volume":"20","author":"WH Miller","year":"2005","unstructured":"Miller, W. H. et al. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother. Radiopharm. 20, 436\u2013449 (2005).","journal-title":"Cancer Biother. Radiopharm."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-019-0327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-019-0327-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-019-0327-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:49:26Z","timestamp":1671302966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-019-0327-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1038\/s42003-019-0327-4","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"9 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.P.W. is a co-founder of Archeus Technologies, LLC, of which Z.S.M. is a member of the Scientific Advisory Board, and R.H. and J.J.G. are consultants. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"79"}}